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Abstract
Background: DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing
therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end
joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC).
Methods: qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins
related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ
pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was
used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on
patients with HCC treated with transarterial chemoembolization (TACE).
Results: Many conventional cancer chemotherapeutics induce DNA double-strand breaks (DSBs). HCC cells respond to
these breaks by increasing their NHEJ activity, resulting in resistance. XLF-knockdown cells show an inhibition of NHEJ
activity in both cell-free and live-cell assays as well as a high level of unrepaired cellular DSBs. These results indicate that
XLF facilitates DNA end-joining and therefore promotes NHEJ activity in cancer cells. Consequently, knockdown of XLF
significantly chemosensitized resistant cells both in vitro and in xenograft tumors. A low rate of XLF genomic alteration
was found in patients with primary HCC, but XLF expression was induced after drug treatment. Clinically, a high level of
XLF expression is significantly associated with advanced HCC and shorter overall survival.
Conclusion: Chemotherapy-induced overexpression of XLF and XLF-mediated enhancements in NHEJ activity contribute
to chemoresistance in HCC cells and patients with HCC. Targeting XLF to modulate DSB repair could enhance drug
sensitivity and may be a therapeutically useful addition to conventional therapy.
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Background
Many chemotherapeutic drugs induce DNA damage. Drug-
induced DNA lesions are recognized by DNA damage re-
sponse (DDR) factors, which activate cell cycle checkpoints
and direct DNA repair pathways. These events enable
tumor cells to survive chemotherapy. Therefore, the effect-
iveness of DNA-damaging drugs largely depends on the
DNA damage repair capacity of a cancer cell. Using a com-
bination of DNA-damaging drugs and drugs targeting DDR
and DNA damage repair pathways is an obvious
therapeutic strategy for cancer, not only to enhance thera-
peutic sensitivity but also for targeted cancer therapy [1–4].
Current DDR-targeting therapies include (a) restoration of
wild type p53 activity, as commonly occurring mutations
can inactivate p53 and consequently abrogate cell cycle
checkpoints; (b) direct inhibition of cell cycle checkpoint
regulators, leading to cell death; and (c) inhibition of DNA
damage repair pathways, causing general disease-associated
deregulation of DNA repair [1, 4].
Cancers often develop defects in genes associated with
DNA repair pathways. Therapeutic interventions targeting
proteins with functions dispensable for normal cells but es-
sential for cancer cell survival provide synthetic sensitivity
or lethality (SSL) [4, 5]. As expected, due to the severe
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consequences associated with unrepaired DSBs, the hom-
ologous recombination (HR) and non-homologous end
joining (NHEJ) pathways display a high level of SSL with
many other pathways. For example, PARP1, a PARP inhibi-
tor, creates synthetic lethality in HR-deficient cancers, such
as breast and ovarian tumors harboring BRCA1 and
BRCA2 gene mutations [2, 4, 6]. However, resistance to
PARP inhibitors has been reported [7], and crosstalk be-
tween DNA repair pathways such as the HR and NHEJ
pathways could result in the acquisition of resistance mech-
anisms in tumors [3]. Thus, the identification of novel DDR
targets is needed and requires further investigation [4].
Direct double-strand breaks (DSBs) are considered the
most lethal type of DNA lesion [8]. DSBs induced by ioniz-
ing radiation (IR) and radiomimetic drugs are mainly
repaired by NHEJ [9], whereas replication-associated DSBs
are repaired by HR and related replication repair pathways
[10]. Unlike HR, which is restricted in the S and G2/M
phases of the cell cycle, NHEJ is active throughout the cell
cycle and is the only DSB repair mechanism available in G1,
during which there is no template for HR [1]. Well-
characterized core members of the NHEJ pathway include
KU70/KU80, DNA-dependent kinase (DNA-PKcs),
Artimes, ligase 4 (LIG4), X-ray-cross-complementation
gene 4 (XRCC4), and XRCC4-like factor (XLF). DNA-PKcs
regulatory subunits KU70 and KU80 bind to DSB ends and
dictate NHEJ pathway choice. In association with XRCC4
and XLF, LIG4 ligates exposed ends of DNA [1, 11]. A re-
cently identified component of the NHEJ pathway in human
cells is PAXX (Paralog of XRCC4 and XLF), which func-
tions in concert with XRCC4 and XLF to mediate DSB re-
pair [12]. XLF (also called Cernunnos or NHEJ1) has
recently been identified as a core NHEJ factor. XLF-null hu-
man cells are highly sensitive to IR and have profound DBS
repair defects. The absence of XLF also leads to V(D)J re-
combination defects (13, 14).
Chemotherapy is a principal treatment for cancer, but re-
sistance to chemotherapy drugs and molecular targeted
therapeutics creates a major obstacle for cancer therapy.
Hepatocellular carcinoma (HCC) is a highly chemoresistant
cancer with limited therapeutic options. Many types of can-
cers have been shown to possess DDR gene mutations and
DDR pathway gene dis-regulation [1, 4]; however, these fea-
tures have not been identified in HCC [4]. Thus, for HCC,
whether the DDR pathway is deregulated and how this
pathway is related to therapy resistance are not well de-
fined. In this study, we investigated the roles of XLF-
mediated NHEJ in drug response and resistance in HCC.
Methods
Cell culture and drug sensitivity
The HCC cell lines PLC/PRF/5 (ATCC, CRL-8024), Huh7
(provided by Dr. H Nakabayashi, Hokkaido University,
Japan), MHCC97 L (97 L) and MHCC97H (97H)
(provided by Liver Cancer Institute of Fudan University,
China) were cultured in DMEM containing 10% FBS.
CD133-PE-labeled Huh7 cells were sorted using magnetic
microbeads conjugated to an anti-PE antibody (Miltenyi
Biotec. Germany). Sorted CD133+ and CD133− cells were
cultured for further experiments. The chemotherapeutic
drugs cisplatin (cis, Mayne Pharma, Melbourne,
Australia), oxaliplatin (oxa, Jiangsu Hengrui Medicine Co.,
China), doxorubicin (dox, Main Luck Pharmaceuticals,
China), and 5-fluorouacial (5FU, Sigma-Aldrich, St. Louis,
MO) were applied to cells, and cell viability was deter-
mined by incubation with tetrazolium salt (Cell Counting
Kit 8, Dojindo, Japan) and using colony-forming assays.
Transfection
Small interfering RNAs (siRNAs) against human XLF and
ERCC1 (Santa Cruz Biotechnology, Dallas, TX) were trans-
fected into 97 L cells using Lipofectamine RNAiMAX (Life
Technologies, Carlsbad, CA). Scrambled siRNA was used
as a negative control. shRNA against human NHEJ1 and a
scrambled control were constructed using a pEco-Lenti-
H1-shRNA (GFP) kit (GenTarget Inc., San Diego, CA).
Lentivirus particles were produced in 293 T cells using
ViraPower Lentiviral Packaging Mix (Life Technologies)
and concentrated by ultracentrifugation (20,000 g). 97 L
cells were infected with shXLF or shCon lentiviral particles,
followed by puromycin selection for 7–10 days.
Antibodies, western blotting, and immunofluorescence
A phospho-histone H2AX (Ser139) (γH2AX) antibody
was obtained from Cell Signaling Technology (Beverly,
MA). An antibody against Ligase IV was purchased from
Santa Cruz Biotechnology (Santa Cruz Biotechnology,
Dallas, Texas), and an ERCC1 antibody was purchased
from Thermo Fisher Scientific (Waltham, MA). For west-
ern blotting (WB), PVDF membranes containing proteins
electrophoretically separated from cell lysates were probed
with relevant antibodies. The resultant immune com-
plexes were visualized using enhanced chemiluminescence
detection reagents (Bio-Rad, Hercules, CA). For immuno-
fluorescence staining, cells were harvested and cyto-spun,
followed by fixation with 4% paraformaldehyde. After
blocking and permeabilization with 1%BSA/0.3%Triton-
X100 in PBS for 1 h, the cells were incubated with anti-
γH2AX antibody overnight at 4 °C. A FITC-conjugated
secondary antibody (Life Technologies) was utilized to
visualize the signal.
Cell-free (in vitro) and living cell (in vivo) NHEJ assays
For the in vitro NHEJ assay, cellular nuclear protein frac-
tions were isolated and applied to repair DNA DSBs in
vitro as previously described [15]. Briefly, cellular nuclear
protein was incubated with linearized plasmid DNA in T4
ligase buffer and 1 mM dNTPs for 2 h at 14 °C. After de-
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proteinization, the quantity of end-joined DNA products
was measured by quantitative PCR with a pair of primers
flanked primer-joining junction of the plasmid. Relative
NHEJ activity was calculated as the ratio of end-joined
products normalized to the loading control. For the in
vivo NHEJ assay, the engineered construct pEGFP-PEM1-
Ad2 [16] was transfected using X-tremeGENE HP reagent
(Roche, Hong Kong). The starting construct was GFP-
negative, and the successful repair of Hind III-induced
DSBs by cellular NHEJ was identified by restored func-
tionality of the GFP gene [16]. After transfection, the
number of GFP-positive cells was measured by flow cy-
tometry and normalized to the transfection efficiency for
in vivo NHEJ activity.
Xenograft tumor model
97 L cells (1 × 106) infected with lentiviruses harboring
shRNA-XLF or shRNA-scramble were subcutaneously
injected into nude mice to generate an HCC xenograft
model. Two weeks after tumor cell injection, 4 cycles of
oxaliplatin (4–10 mg/kg) were given via weekly intraper-
itoneal injection. Tumor volumes were measured at the
endpoint. Nuclear proteins from the xenograft tumors
were extracted to perform cell-free NHEJ assays. All ani-
mal experiments were approved by the Committee on
the Use of Live Animals of The University of Hong Kong
(CULATR 3091–13).
HCC tumor specimens
Tissue specimens were collected from 31 patients with
HCC who received transarterial chemoembolization
(TACE) as a first treatment followed by a hepatectomy.
All patients were treated at Queen Mary Hospital. Tis-
sue specimens were also collected from patients with
HCC who underwent hepatectomy as a first treatment.
This study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Author-
ity of Hong Kong (UW05–3597/I022). The need for in-
formed consent was waived because the study was
retrospective in design.
Statistical analysis
Data are presented as the mean ± SD. Paired and inde-
pendent Student’s t tests were performed using SPSS 21
software (IBM Corp. Armonk, NY). Overall and disease-
free survival rates for the included patients were ana-
lyzed using the Kaplan-Meier log-rank method.
Results
Therapy sensitivity is associated with NHEJ activity
To better understand how DNA damage repair contrib-
utes to HCC therapy resistance, we first investigated the
correlation between the presence of DNA lesions induced
by chemotherapeutic drugs and cellular sensitivity. To
accomplish this, three types of drugs with different DNA-
damaging mechanisms were applied. γH2AX nuclear foci
staining was used to detect DSBs: within minutes of the
occurrence of DNA damage, H2A.X becomes phosphory-
lated at Ser139 (γH2AX) at sites of damage [17]. Cisplatin
and oxaliplatin (DNA crosslinking agents), doxorubicin
(topoisomerase II inhibitor), and 5-FU (antimetabolites)
can all induce DSBs both directly and indirectly (Fig. 1a).
Following treatments with these drugs, 25% to 50% of
97 L and PLC cells showed positive staining for γH2AX in
nuclear foci (Fig. 1b). The γH2AX-positive nuclear foci
peaked at 9 h after drug treatment (Fig. 1c). Interestingly,
at 48 h, the percentage of γH2AX-positive cells in the
97 L cell group was significantly reduced (Fig. 1c, right
panel) compared to that in the PLC cell group, where the
percentage remained high (Fig. 1c, left panel). This result
indicates that these two cell lines harbor differences in
their DSB repair capacity.
We further compared NHEJ activity in vitro and in vivo.
Nuclear proteins were isolated from drug-treated cells to
perform in vitro NHEJ assays using double-stranded plas-
mid DNA as a substrate. NHEJ activity in 97 L cells was
5- to 10-fold higher in cells submitted to drug treatment
compared to untreated cells. In contrast, NHEJ activity in
PLC cells did not change in response to drug treatment
(Fig. 1d). Similarly, the drugs oxaliplatin and doxorubicin
induced NHEJ activity in 97 L cells in live-cell assays but
not in PLC cells (Fig. 1e). Thus, 97 L cells displayed sig-
nificantly higher in vitro and in vivo NHEJ activity than
PLC cells. Concordantly, we found that PLC cells were
sensitive to the drugs, whereas 97 L cells were resistant to
them (Fig. 1f). The half maximal inhibitory concentration
(IC50) for oxaliplatin for inducing HCC cell death was
consistently significantly higher in 97 L cells (4.8 μg/ml)
than in PLC cells (2.6 μg/ml) (Fig. 1g). Thus, conventional
chemotherapeutic drugs for HCC treatment can induce
DSBs, and NHEJ responses following treatment with
DNA-damaging drugs differ among different cells. HCC
cells (97 L) with increased NHEJ activity are more resist-
ant to drugs, whereas HCC cells (PLC) with no enhance-
ment of NHEJ activity are more sensitive.
Liver CSCs possess high NHEJ capacity
Cancer stem cells (CSCs) are highly resistant to chemo-
therapeutic drugs [18, 19]. We found that a correlation
exists between relative chemotherapeutic response and
NHEJ activity in HCC CD133+ (potential CSC popula-
tion) and CD133− populations. In studying Huh7-
CD133+ and Huh7-CD133− populations, we found that
the former was more drug resistant than the latter, with
75–85% of CD133+ cells surviving after oxaliplatin or
doxorubicin treatment (Fig. 2a). When investigating
whether NHEJ mechanisms contribute to liver CSC re-
sistance, we found that gene expression levels of the
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NHEJ factors Ku, DNA-PKcs, and XLF were significantly
higher in CD133+ than in CD133− cells (Fig. 2b). We
next transfected pEGFP-PEM1-Ad2 plasmids into both
CD133+ and CD133− populations and then observed
drug-induced NHEJ activity in vivo. The CD133+ cells
contained a significantly higher GFP+ population than
the CD133− cells (Fig. 2c), and this pattern was consist-
ent with all three drug treatments (Fig. 2c). This result
indicates that DSB repair capacity in CD133+ cells is
higher than in CD133− cells. Statistical comparisons of
the in vivo NHEJ assay results are summarized in Fig.
2d. The results indicate that significantly higher NHEJ
activity is found in CD133+ cells. These results suggest
that CSCs possess higher intrinsic NHEJ capacity.
XLF knockdown enhances chemosensitivity in HCC cells
XLF is a core member of the NHEJ protein complex.
XLF interacts with XRCC4 to form an XRCC4/XLF
dimer that bridges DNA ends in vitro; thus, XLF might
stimulate ligation [20–22]. XLF also accumulates at sites
with DSBs [14]. Whether the known functions of XLF
have a role in drug-induced DSB repair and cancer re-
sistance is not known. Resistant 97 L HCC cells dis-
played high NHEJ activity both in vitro and in vivo (Fig.
1d, e). After knocking down XLF, the drug-induced in
vitro NHEJ activity was significantly inhibited (Fig. 3a).
In vivo, NHEJ activity was still induced by the drugs in
shRNA-control-transfected cells, whereas it was not in
cells transfected with shRNA-XLF (Fig. 3b). These
Fig. 1 Chemosensitivity in HCC cells is associated with drug-induced increases in NHEJ activity. a Following conventional therapy regimens with
the drugs cisplatin (cis), oxaliplatin (oxa) doxorubicin (dox), as well as treatment with 5-FU, DSB foci in PLC and 97 L cells were localized using an
anti-γH2AX antibody. b Quantification of the percentage of γH2AX foci-positive cells. Data are reported as the mean ± SD from 2 independent
experiments. c Statistical comparison of the percentage of γH2AX-positive cells between PLC and 97 L groups at 9 h and 48 h after drug
treatment. A total of 1000 cells were randomly selected for counting. The mean ± SD was from 3 independent experiments. p values ≤0.05 and
≤0.01 were denoted as * and **, respectively. d In vitro NHEJ activity was assayed after oxaliplatin and doxorubicin treatment and quantified by
plasmid-based quantitative PCR (see methods). NHEJ activity from 3 independent experiments was statistically analyzed using a paired Student’s t
test. e HCC cells were transfected with the plasmid pEGFP-PEM1-Ad2, followed by drug treatment. In vivo NHEJ activity was calculated based on
the frequency of GFP-positive cells normalized to the transfection efficiency. Drug-induced NHEJ activity was counted as a ratio of drug-induced
activity versus control activity. Representative data are reported as the mean ± SD, n = 3. f PLC and 97 L cells were treated with cisplatin (1 μg/
ml), oxaliplatin (1 μg/ml), or doxorubicin (0.2 μg/ml). Cell viability (%) was determined using a Cell Counting Kit 8 and standardized against cells
without drug treatment. Representative data are reported as the mean ± SD, n = 3. g The therapy drug (oxaliplatin) response curve and the IC50
concentration for the PLC and 97 L cells were analyzed from 2 independent experiments using GraphPad 6.0
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Fig. 2 Liver CD133+ CSCs possess high intrinsic NHEJ capacity. a Statistical comparison of drug sensitivity in CD133+ and CD133− liver cancer cells
measured by cell viability assays. b Expression levels of the NHEJ genes Ku, DNA-PK, and XLF in CD133+ and CD133− HCC cells determined by qRT-
PCR. Expression levels were normalized to the reference gene 18S rRNA. The data are reported as the mean ± SD obtained from 2 experiments with
duplicates. c Huh7 cells were transfected with pEGFP-PEM1-Ad2 plasmid, followed by cisplatin, oxaliplatin, or doxorubicin treatment. GPF+ gating was
based on CD133-PE-positive (upper part) and CD133-PE-negative (lower part) populations. Live-cell NHEJ activity is presented as the percentage of GFP
+ cells within CD133+ and CD133− cell populations and was normalized to the transfection efficiency. d Statistical comparison of drug-induced NHEJ
activity in vivo of c between CD133+ and CD133− cells from 2 independent experiments
Fig. 3 Knockdown of XLF chemosensitizes resistant 97 L cells by causing inhibition of NHEJ activity. a In vitro NHEJ activity was assayed and quantified
in shRNA-Con and shRNA-XLF lentivirus-infected 97 L cells from 3 independent experiments. b In vivo NHEJ activity was calculated as the percentage
of GFP-positive cells and normalized to transfection efficiency for the shCon and shXLF group, which were transfected with pEGFP-PEM1-Ad2 plasmid
and treated with or without oxaliplatin. The data are reported as the mean ± SD, n = 4. c Quantification of the percentage of cells with <5 and >5
γΗ2ΑX foci per nucleus at 26 h after drug treatment for the siRNA-Con and siRNA-XLF groups (left panel). The data are reported as the mean ± SD,
n = 2. Image of γH2AX speckles with <5 and >5 foci per nucleus (right panel). d Statistical comparison of drug sensitivity based on colony formation
assay results from shCon and shXLF cells. Number of colonies is reported as the mean ± SD from 2 independent experiments. e Gene expression levels
(left panel) and protein levels (right panel) of LIG4 and ERCC1 were determined by qRT-PCR and WB, respectively, in shCon and shXLF HCC cells. f
Cisplatin response curves and IC50 concentrations for siCon, siXLF, siERCC1, and siXLF + siERCC1 cells, respectively. Statistical comparison was between
siXLF, siERCC1, and siXLF + siERCC1 versus siCon, respectively, with treatment by cisplatin 1 or 5 μg/ml. * p < 0.05; ** p < 0.01; *** p < 0.001
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results imply that down-regulating XLF significantly im-
pairs NHEJ capacity. 97 L cells had higher DSB repair ef-
ficiency, and γH2AX foci were reduced after longer-term
drug treatment (Fig. 1c). Following XLF knockdown, the
number of γH2AX foci remained high, with 83.1% ± 6.1
of cells displaying >5 γH2AX foci (Fig. 3c), indicating
the presence of unrepaired DSBs. As a result, 97 L cells
became sensitized to the chemotherapeutic drugs tested
(Fig. 3d).
XLF knockdown results in down-regulation of ERCC1
We next explored the cross-regulation of XLF with other
DNA repair genes, such as LIG4, as XLF stimulates the
XRCC4/LIG4 complex [13]. We also investigated excision
repair cross-complementing 1 (ERCC1) of the nucleotide
excision repair (NER) pathway. Achieving SSL is ideal for
producing therapeutic effects, and the HR and NHEJ
pathways show high levels of SSL with the NER pathway
[4]. Down-regulation of XLF was associated with reduced
LIG4 mRNA (Fig. 3e, left panel) and protein expression
levels (Fig. 3e, right panel), which is consistent with previ-
ous findings that XLF regulates LIG4 in cancer. Interest-
ingly, in XLF-knockdown cells, ERCC1 mRNA and
protein expression levels also decreased (Fig. 3e). We then
investigated whether a synergistic effect exists between
the chemotherapeutic drugs after two DNA repair genes
are inhibited. In combination with ligase inhibitor (L189),
the drugs inhibited the growth of shXLF cells more than
the growth of shCon cells (Additional file 1: Fig. S1). Inhi-
biting XLF enhanced the chemotherapeutic sensitivity in
resistant 97 L HCC cells (Fig. 3d). We then determined a
synergistic effect compared to cisplatin alone, particularly
when both XLF and ERCC1 were knocked down because
ERCC1 positive-tumors predict cisplatin resistance in
non-small-cell lung cancer and squamous cell carcinoma
[23–25]. The IC50 of cisplatin was 5.56 μg/ml for the
siCon group, 3.15 μg/ml for the siXLF group, 2.51 μg/ml
for the siERCC1 group, and 1.43 μg/ml for the siXLF +
siERCC1 group (Fig. 3f), indicating a chemosensitization
effect when there was knockdown of either XLF or
ERCC1, where the most enhanced chemosensitivity was
seen with knockdown of both XLF and ERCC1. Crosstalk
between DNA repair pathways often results in the acquisi-
tion of resistance mechanisms in cancer [3]. This result
suggests that targeting independent pathways may pro-
duce stronger synergy than targeting the same pathway at
multiple points [2].
XLF knockdown enhances therapeutic efficacy in HCC
xenograft model
To establish a xenograft model, shCon- and shXLF-
transfected 97 L cells were subcutaneously injected into
the left and right flanks, respectively, of the same nude
mouse. Using the drug administration protocol depicted
in Fig. 4a, oxaliplatin treatment was started at the third
week after cell injection and was continued for 4 weeks.
At the endpoint, overall tumor volumes were signifi-
cantly smaller for the shXLF-HCC xenografts than the
shCon-HCC xenografts (Fig. 4b, c), indicating that XLF
knockdown sensitized HCC xenografts to oxaliplatin.
Cell-free NHEJ activity was measured in nuclear proteins
extracted from xenograft tissue. A dramatic enhance-
ment in NHEJ activity was observed in the shCon xeno-
grafts, whereas NHEJ activity was consistently inhibited
in the shXLF xenografts (Fig. 4d). Thus, the shXLF-HCC
xenograft tumors were more responsive to oxaliplatin as
a result of shXLF-mediated reductions in NHEJ activity.
Low frequency of XLF gene alterations in patients with
HCC
Cancer cells are frequently dysfunctional in one or more
DDR and DNA damage repair pathways, which can be spe-
cifically inhibited to induce SSL. These dysfunctions can
also lead to additional alterations in DDR pathways that
may induce therapy resistance [1, 4]. Given that XLF-
mediated induction of NHEJ activity in HCC cells is associ-
ated with chemotherapeutic drug sensitivity (Figs. 1 and 2),
we investigated the incidence of XLF gene alterations using
bioinformatic analysis. We also investigated genomic alter-
ations of the core factors in the NHEJ pathway in HCC and
other cancers. The NHEJ pathway includes 8 genes: NHEJ1
(XLF), XRCC4, XRCC5, XRCC6, LIG4, DNA-dependent
protein kinase catalytic subunit (PRKDC), TP53BP1, and
DNA cross-link repair 1C (DCLRE1C). Genomic alter-
ations were identified using cBioPortal [http://www.cbio-
portal.org] [26, 27] based on 90 studies from 17 to 26 types
of primary tumor and cancer lines assembled by The Can-
cer Genomics Atlas (TCGA) [28] and Asan Medical Center
(AMC) [29]. The frequency of alterations, including muta-
tion, deletion, amplification, and multiple alterations, for
NHEJ pathway genes in HCC was found to be 17.6% by
TCGA and 10% by AMC (Additional file 1: Fig. S2); in con-
trast, the frequency of alterations in the XLF gene was ex-
tremely low in HCC. Indeed, only one of 231 patients had a
missense mutation (mutation rate: 0.4%)(Fig. 5a) in the
AMC data collection, and no mutations were found in the
371 patients included in the TCGA data collection (Add-
itional file 1: Fig. S3; Additional file 2: Table S1). Moreover,
upregulation of XLF mRNA was found in only 5% of pa-
tients with HCC (Additional file 2: Table S1). Given the low
genomic alteration rate of XLF in patients with HCC, we
sought to measure XLF levels in primary HCC tissues from
patients who did or did not receive TACE treatment before
liver tumor resection to determine whether therapy drugs
can impact XLF expression, because TACE delivers chemo-
therapy in combination with embolization to administer
therapy directly to liver tumors. As shown in Fig. 5b, XLF
expression was significantly increased in patients with HCC
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Fig. 4 XLF knockdown restores drug sensitivity in HCC xenograft model. a Experimental setup used to create the xenograft model. shCon and shXLF
97 L cells (1 × 106) were subcutaneously injected into nude mice. Oxaliplatin (4 mg/kg/week or 10 mg/kg/week) was administered to the mice by
intra-peritoneal injection. b Tumor volume was reported in mm3 as the mean ± SD and statistically compared between shCon and shXLF tumors.
c Representative images of xenograft tumor. d In vitro NHEJ activity in nuclear proteins extracted from xenograft tumor tissue. The statistical
comparison was based on the mean ± SD from 3 independent experiments
Fig. 5 Clinical significance of XLF expression. a Genomic alteration frequency for XLF was calculated using cBioPortal [http://www.cbioportal.org] from the
TCGA (193 patients) and AMC (231 patients) databases. Tumor types are indicated at the bottom and ordered by the frequency of samples harboring
mutation, deletion, amplification and multiple alterations. The XLF mutation rate in HCC is highlighted. b Statistical comparison of XLF gene expression in
tumor tissue between patients with HCC who underwent TACE (n = 31) and those who did not (n = 22). c Kaplan-Meier analysis of overall survival
between patients with HCC with high and low expression of XLF, who all underwent TACE treatment. d Kaplan-Meier analysis of disease-free survival for
patients with HCC as in c
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who underwent TACE compared to those who did not, in-
dicating that the delivery of drugs by TACE may directly or
indirectly stimulate XLF expression.
Therapy drugs induce XLF expression and affect clinical
outcome
Given that XLF expression (Fig. 5b) and XLF-mediated al-
terations in NHEJ activity (Fig. 1d, e; Fig. 3a, b) can be in-
duced by therapy drugs, we wanted to assess whether
enhancing XLF expression would affect HCC clinical pa-
rameters. The patients in the TACE treatment group who
showed higher levels of XLF expression displayed poor
prognosis features such as larger tumor size, venous infil-
tration, and advanced-stage HCC disease (Table 1). More
importantly, XLF expression was significantly associated
with overall survival of HCC patients, with patients exhi-
biting higher levels of XLF showing shorter survival times
(Fig. 5c). High XLF expression was also associated with a
shorter disease-free survival time, although the trend did
not reach statistical significance (Fig. 5d).
Discussion
Cancer cells frequently exhibit dysfunctional DNA repair.
Mutations in DNA repair pathways can also be a predis-
posing factor for cancer. However, once tumors develop,
DNA repair pathways can be used by cancer cells to over-
come many standard anticancer treatments and are often
a cause of chemotherapeutic resistance [30]. DDR path-
way deregulation has been analyzed in 15 types of cancer
[4], although there have been no previous reports describ-
ing this deregulation in HCC [4]. Based on a large dataset
assembled by TCGA and AMC with information from 17
to 26 types of primary tumor and cancer lines, we showed
here for the first time the genomic alterations that can be
found in core factors of NHEJ pathway, including XLF, in
patients with HCC. Our analysis demonstrated an ex-
tremely low mutation rate (0.4%) for XLF in the AMC
data collection and no mutations for XLF in the TCGA
data collection for patients with HCC. Furthermore, XLF
mRNA overexpression was found in only 5% of patients
with HCC. These results suggest that dysregulation of
XLF does not contribute to the phenotypic profile of
HCC. However, significant upregulation of XLF was ob-
served in patients who underwent TACE, indicating that
therapeutic drugs can induce overexpression of XLF. This
overexpression was further predictive of poor prognosis
and reduced survival. These results led us to develop a
new hypothesis: therapy resistance associated with DNA
repair can be induced by standard therapeutic treatment
and might not be related to pre-existing deregulation of
DNA repair pathways. This hypothesis is reinforced by
clinical observations that TACE therapy induces robust
XLF expression and that XLF induces high levels of NHEJ
activity in patients with HCC. These patients might de-
velop DNA repair-mediated therapy resistance, a critical
contributor to treatment failure and reduced survival,
even after hepatectomy. Thus, rationale for including
DNA repair inhibitors as part of the cancer drug arma-
mentarium should be based not only on the presence of
abnormally high levels of intrinsic expression of DNA re-
pair pathway members in tumor tissue but also on high
levels of expression induced by chemotherapeutic drugs.
By comparing two HCC cell lines with different de-
grees of drug sensitivity, we determined that conven-
tional chemotherapy can induce NHEJ activity in HCC
cells. Increases in NHEJ activity leads to the repair of
drug-induced DSBs and reduces the presence of cellular
γH2AX foci, which significantly decreased the effective-
ness of the chemotherapeutic drugs used in this study.
Drug-induced activation of NHEJ activity also contrib-
uted to the chemoresistance of liver CSCs. We further
demonstrated that XLF plays an important role in drug
resistance mediated by NHEJ activity. Knocking down
XLF significantly enhanced chemosensitization in vitro
and in vivo by decreasing NHEJ activity. Thus, for the
first time, we have demonstrated that XLF-mediated in-
creases in NHEJ activity are responsible for chemoresis-
tance in HCC cells. The XLF-XRCC4 complex is
essential for NHEJ, although how XLF mechanistically
functions in NHEJ is not well understood [31]. Recent
studies have suggested that XLF-XRCC4 filaments pro-
vide both protection to and alignment of DNA ends for
accurate and efficient ligation [31, 32]. Whether this
mechanism is relevant in our current experimental set-
ting is not known. However, downregulation of XLF sig-
nificantly impaired ligation and thus reduced NHEJ
efficiency, resulting in 80% of γH2AX-positive cells con-
taining >5 γH2AX foci per cell as well as the develop-
ment of chemosensitization. Moreover, XLF might
directly regulate LIG4, as knocking down XLF downreg-
ulated LIG4. Together, the roles of the XLF-XRCC4
complex in promoting ligation [31] and XLF-stimulated
NHEJ activity in chemoresistance suggests that targeting
Table 1 Correlation between XLF expression and
clinicopathologic features in TACE-treated HCC
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XLF is a potential avenue for the development of a new
DNA repair inhibitor for combination therapy.
DNA-dependent protein kinase catalytic subunit (DNA-
PKcs), including Ku70 and Ku80, plays key roles in NHEJ
repair for DSB repair and V(D)J recombination. Recent in-
vestigations demonstrated that levels of DNA-PKcs were
directly associated with genomic stability, cancer cell pro-
liferation index, and patients’ survival length in HCC, sug-
gesting that DNA-PKcs contributes to liver malignant
transformation and carcinogenesis. Moreover, elevated
DNA-PKcs expression identified HCC patients with
therapy-resistance [33, 34]. In combination with our study,
intrinsic and drug-induced DNA repair genes of the NHEJ
pathway indeed represent prognostic factors and, more
importantly, specific therapeutic targets.
γH2AX phosphorylation occurs several minutes after ir-
radiation and DSB formation. Immunological detection of
γH2AX indicates the presence of unrepaired DNA breaks.
Thus, γH2AX has been utilized as a pharmacodynamic
marker in clinical studies. For example, γH2AX foci were
enumerated to determine irradiation toxicity at different
dosages and to evaluate chemotherapeutic drug responses
[4, 35, 36]. According to our observations, the remaining
levels but not initial level of γH2AX positive cells is a bet-
ter predictor for drug sensitivity. Many cancer cells pos-
sess high DNA repair capacity, and the number of
γH2AX-positive cells and foci after longer-term drug
treatment are predictive of cellular response or resistance.
Conclusion
Overexpression of XLF and increased NHEJ activity me-
diated by XLF in response to treatment with chemother-
apeutic drugs contribute to chemoresistance in HCC
cells and patients with HCC. Inhibition of XLF-mediated
NHEJ activity results in chemosensitization in a HCC
xenograft model, suggesting that XLF is a novel candi-
date for the development of new DNA repair inhibitors
for combination therapy.
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